NASDAQ:TFFP TFF Pharmaceuticals (TFFP) Stock Price, News & Analysis $1.88 +0.11 (+6.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.78▼$1.9150-Day Range$1.57▼$2.2952-Week Range$1.54▼$13.50Volume9,812 shsAverage Volume32,537 shsMarket Capitalization$5.81 millionP/E RatioN/ADividend YieldN/APrice Target$44.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get TFF Pharmaceuticals alerts: Email Address TFF Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,246.7% Upside$44.00 Price TargetShort InterestHealthy4.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.51) to ($6.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.20 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTFF Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTFF Pharmaceuticals has received no research coverage in the past 90 days.Read more about TFF Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.71% of the float of TFF Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTFF Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TFF Pharmaceuticals has recently decreased by 5.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTFF Pharmaceuticals does not currently pay a dividend.Dividend GrowthTFF Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TFFP. Previous Next 3.3 News and Social Media Coverage News SentimentTFF Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TFF Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for TFFP on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added TFF Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TFF Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of TFF Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 15.25% of the stock of TFF Pharmaceuticals is held by institutions.Read more about TFF Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TFF Pharmaceuticals are expected to grow in the coming year, from ($6.51) to ($6.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TFF Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TFF Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTFF Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TFF Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About TFF Pharmaceuticals Stock (NASDAQ:TFFP)TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.Read More TFFP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TFFP Stock News HeadlinesJune 26, 2024 | globenewswire.comTFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing OpportunitiesJune 19, 2024 | investorplace.com3 52-Week-Low Losers Ready to Become Big-Time Stock WinnersJuly 26, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 23, 2024 | globenewswire.comTFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical TestingMay 20, 2024 | globenewswire.comTFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical TestingMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market PotentialMay 15, 2024 | globenewswire.comTFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant RejectionMay 15, 2024 | investorplace.comTFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024July 26, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 14, 2024 | globenewswire.comTFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate UpdateMay 1, 2024 | globenewswire.comTFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public OfferingApril 29, 2024 | globenewswire.comTFF Pharmaceuticals Announces Pricing of $4.8 Million Public OfferingApril 29, 2024 | reuters.comTurkish federation investigates match-fixing allegations in third-tier gameApril 29, 2024 | globenewswire.comTFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual MeetingApril 17, 2024 | msn.comTFF Pharmaceuticals (TFFP) Price Target Decreased by 28.99% to 24.99April 15, 2024 | markets.businessinsider.comTFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation PowderApril 15, 2024 | globenewswire.comTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract SessionsApril 1, 2024 | finance.yahoo.comTFF Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsSee More Headlines Receive TFFP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TFF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TFFP CUSIPN/A CIK1733413 Webwww.tffpharma.com Phone817-438-6168FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$44.00 High Stock Price Target$44.00 Low Stock Price Target$44.00 Potential Upside/Downside+2,246.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($10.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,240,000.00 Net Margins-2,251.52% Pretax Margin-2,251.64% Return on Equity-195.14% Return on Assets-160.47% Debt Debt-to-Equity RatioN/A Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$730,000.00 Price / Sales7.96 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.46Miscellaneous Outstanding Shares3,100,000Free Float2,959,000Market Cap$5.81 million OptionableNo Data Beta1.36 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Harlan F. Weisman (Age 72)President, CEO & Director Comp: $742.5kMr. Kirk Allen Coleman (Age 50)CFO, Treasurer & Secretary Comp: $409.94kDr. Zamaneh Mikhak M.D. (Age 60)Chief Medical Officer Comp: $545.38kKey CompetitorsRedHill BiopharmaNASDAQ:RDHLIterum TherapeuticsNASDAQ:ITRMNeuroBo PharmaceuticalsNASDAQ:NRBOCumberland PharmaceuticalsNASDAQ:CPIXOncternal TherapeuticsNASDAQ:ONCTView All CompetitorsInsiders & InstitutionsWestside Investment Management Inc.Bought 11,266 shares on 7/17/2024Ownership: 1.629%Carlson Capital L PSold 8,600 sharesTotal: $94,600.00 ($11.00/share)Harlan F WeismanBought 24,000 shares on 8/15/2023Total: $150,000.00 ($6.25/share)Zamaneh MikhakBought 4,800 shares on 8/15/2023Total: $30,000.00 ($6.25/share)Stephen RocamboliBought 800 shares on 8/15/2023Total: $5,000.00 ($6.25/share)View All Insider TransactionsView All Institutional Transactions TFFP Stock Analysis - Frequently Asked Questions How have TFFP shares performed this year? TFF Pharmaceuticals' stock was trading at $7.02 at the beginning of the year. Since then, TFFP shares have decreased by 73.3% and is now trading at $1.8750. View the best growth stocks for 2024 here. How were TFF Pharmaceuticals' earnings last quarter? TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) posted its earnings results on Tuesday, May, 14th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.20) by $0.20. The business had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.15 million. TFF Pharmaceuticals had a negative trailing twelve-month return on equity of 195.14% and a negative net margin of 2,251.52%. When did TFF Pharmaceuticals' stock split? Shares of TFF Pharmaceuticals reverse split before market open on Tuesday, December 19th 2023. The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did TFF Pharmaceuticals IPO? TFF Pharmaceuticals (TFFP) raised $22 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 4,400,000 shares at $5.00 per share. National Securities served as the underwriter for the IPO. Who are TFF Pharmaceuticals' major shareholders? Top institutional investors of TFF Pharmaceuticals include Westside Investment Management Inc. (1.63%). Insiders that own company stock include Carlson Capital L P, Harlan F Weisman, Aaron GL Fletcher, Zamaneh Mikhak, Stephen Rocamboli, Glenn R Mattes, Kirk Allen Coleman and Randy H Thurman. View institutional ownership trends. How do I buy shares of TFF Pharmaceuticals? Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TFF Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), VYNE Therapeutics (VYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX) and AVEO Pharmaceuticals (AVEO). This page (NASDAQ:TFFP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TFF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TFF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TFFP Stock Alerts